Longitudinal follow-up of antibody response to selected antigens of human papillomaviruses and herpesviruses in patients with invasive cervical carcinoma

International Journal of Cancer

Volumn 89, Issue 2, 2000, Pages 351-355

  Hamšíková, Eva ^a   Ludvíková, Viera ^a   Tachezy, Ruth ^a   Kovařík, Jan ^b   Břoušková, Ludmila ^b   Vonka, Vladimír ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HERPES SIMPLEX VIRUS 1; HUMAN; LONGITUDINAL STUDY; MALIGNANT TRANSFORMATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROCONVERSION; UTERINE CERVIX CARCINOMA; ANTIBODY SPECIFICITY; BLOOD; HERPES VIRUS; IMMUNOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; TIME; UTERINE CERVIX TUMOR; VIROLOGY;

VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; FEMALE; FOLLOW-UP STUDIES; HERPESVIRIDAE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 0034181943     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. BAAY, M.F., DUK, J.M., BURGER, M.P., DE BRUIJN, H.W., STOLZ, E. and HERBRINK, P., Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma. J. med. Virol., 45, 342-347 (1995).
2. BAAY, M.F.D., DUK, J.M., BURGER, M.P.M., DE BRUIJN, H.W.A., STOLZ, E. and HERBRINK, P., Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up. Europ. J. clin. Microbiol. infect. Dis., 18, 126-132 (1999).
3. BOSCH, F.X., MANOS, M.M., MUÑOZ, N., SHERMAN, M., JANSEN, A.M., PETO, J., SCHIFFMAN, M.H., MORENO, V., KURMAN, R. and SHAH, K.V., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J. nat. Cancer Inst., 87, 796-802 (1995).
4. DE GRUIJL, T.D., BONTKES, H.J., WALBOOMERS, J.M.M., SCHILLER, J.T., STUKART, M.J., GROOT, B.S., CHABAUD, M.M.R., REMMINK, A.J., VERBEIJEN, R.H.M., HELMERHORST, T.J.M., MEIJER, C.J.L.M. and SCHEPER, R.J., Immunoglobulin-G responses against human-papillomavirus-type-16 virus-like particles in a prospective non-intervention cohort study of women with cervical intra-epithelial neoplasia. J. nat. Cancer Inst., 89, 630-638 (1997).
5. DE SANJOSE, S. and 14 OTHERS, Serological response to HPV16 in CIN III and cervical-cancer patients. Case-control studies in Spain and Colombia. Int. J. Cancer. 66, 70-74 (1996).
6. DILLNER, J., Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer. Lancet, 341, 1594-1594 (1993).
7. DILLNER, J., Antibody responses to defined HPV epitopes in cervical neoplasia. In: C. Lacey (ed.), Papillomavirus reviews: current research on papillomaviruses, pp. 121-130, Leeds University Press, Leeds (1996).
8. DILLNER, J. and 14 OTHERS, Prospective sero-epidemiologic study of human-papillomavirus infection as a risk factor for invasive cervical cancer. J. nat. Cancer Inst., 89, 1293-1299 (1997).
9. DI LONARDO, A., MARCANTE, M.L., POGGIALI, F. and VENUTI, A., HPV-16 E7 antibody levels in cervical-cancer patients: before and after treatment. J. med. Virol. 54, 192-195 (1998).
10. DI PAOLO, J.A., WOODWORTH, C.D., COUTLEE, F., ZIMONIC, D.B., BRYANT, J. and KESSOUS, A., Relationship of stable integration of herpes-simplex-virus-2 Bg/II N sub-fragment Xho2 to malignant transformation of human-papillomavirus-immortalized cervical keratinocytes. Int. J. Cancer, 76, 865-871 (1998).
11. ELFGREN, K., BISTOLETTI, P., DILLNER, L., WALBOOMERS, J.M., MEIJER, C.J. and DILLNER, J., Conization for cervical intra-epithelial neoplasia is followed by disappearance of human-papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Amer. J. Obstet. Gynecol., 174, 937-942 (1996).
12. FISHER, S.G., BENITEZ-BRIBIESCA, L., NINDL, I., STOCKFLETH, E., MULLER, M., WOLF, H., PEREZ-GARCIA, F., GUZMAN-GAONA, J., GUTIERREZ-DELGADO, F., IRVIN, W. and GISSMANN, L., The association of human-papillomavirus-type-16 E6 and E7 antibodies with stage of cervical cancer. Gynecol. Oncol., 61, 73-78 (1996).
13. GALLOWAY, D.A., HPV serology: another update. In: C. Lacey (ed.), Papillomavirus Reviews: Current Research on Papillomaviruses, pp. 113-119. Leeds University Press, Leeds (1996).
14. GISSMANN, L. and MÜLLER, M., The current role of HPV serology. In: M. Stanley and P. Stern (eds.), Human papillomaviruses and cervical cancer, pp. 133-134, Oxford University Press, Oxford (1994).
15. HAMŠÍKOVÁ, E., LUDVÍKOVÁ, V., ŠMAHEL, M., SAPP, M. and VONKA, V., Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int. J. Cancer. 77, 689-694 (1998).
16. HAMŠÍKOVÁ, E., NOVÁK, J., HOPMANNOVÁ, V., MUÑOZ, N., BOSCH, F.X., DE SANJOSE, S., SHAH, K., ROTH, Z. and VONKA, V., Presence of antibodies to seven human-papillomavirus-type-16-derived peptides in cervical-cancer patients and healthy controls. J. infect. Dis., 170, 1424-1431 (1994).
17. KIRNBAUER, R., HUBBERT, N.L., WHEELER, C.M., BECKER, T.M., LOWY, D.R. and SCHILLER, J.T., A virus-like-particle-enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. nat. Cancer Inst., 86, 494-499 (1994).
18. LENNER, P., DILLNER, J., WIKLUND, F., HALLMANS, G. and STENDAHL, U., Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment and survival in carcinoma of the uterine cervix. Cancer Immunol. Immunother., 40, 201-205 (1995).
19. NONNENMACHER, B., HUBBERT, N.L., KIRNBAUER, R., SHAH, K.V., MUÑOZ, N., BOSCH, F.X., DE SANJOSE, S., VISCIDI, R., LOWY, D.R. and SCHILLER, J.T., Serologic response to human-papillomavinis-type-16(HPV-16)-virus-like particles in HPV-16-DNA-positive invasive cervical cancer and cervical-intra-epithelial-neoplasia-grade-III patients and controls from Colombia and Spain. J. infect. Dis., 172, 19-24 (1995).
20. SUCHÁNKOVÁ, A., RITTEROVÁ, L., KRČMÁR̀, M., KRCHŇÁK, V., VÁGNER, J., JOCHMUS, I., GISSMANN, L., KAŇKA, J. and VONKA, V., Comparison of ELISA and Western blotting for human-papillomavirus-type-16-E7-antibody determination. J. gen. Virol., 72, 2577-2581 (1991).
21. VILADIU, P. and 17 OTHERS, Human papillomavirus DNA and antibodies to human-papillomaviruses-16 E2, L2 and E7 peptides as predictors of survival in patients with squamous-celll cervical cancer. J. clin. Oncol., 15, 610-619 (1997).
22. ZUR HAUSEN, H., Papillomavirus infections - a major cause of human cancers. Biochem. biophys. Acta. 1288, F55-F78 (1996).